NeuroSense Therapeutics Ltd. (NRSNW) Free cash flow 2021–2025
NeuroSense Therapeutics Ltd. (NRSNW) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$7.7MFY2025 · since FY2021: -$1.6M → -$7.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$7.7M | +24.3% |
| FY2024 | -$10.1M | -20.9% |
| FY2023 | -$8.4M | -9.1% |
| FY2022 | -$7.7M | -394.0% |
| FY2021 | -$1.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NRSNW financial trends
NRSNW RevenueNRSNW Net incomeNRSNW Net marginNRSNW Gross profitNRSNW Gross marginNRSNW Operating incomeNRSNW Operating marginNRSNW Operating cash flowNRSNW Capital expendituresNRSNW Return on equityNRSNW Stock buybacksNRSNW Dividends paidNRSNW Total assetsNRSNW Total liabilitiesNRSNW Shareholders’ equityNRSNW overview →